US EditionPublished • loading... • Updated
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Eupraxia Pharmaceuticals raised $63 million through a public offering to fund development of its Diffusphere drug delivery technology targeting unmet medical needs.
- GUANGZHOU, China, March 12, 2026 — Burning Rock Biotech Limited reported unaudited 2025 results and said the USPTO granted its ELSA-seq patent .
- Fiscal 2025, Burning Rock reported RMB539.6 million in revenue and RMB402.9 million in gross profit, with non-GAAP gross profit rising to RMB413.5 million.
- In the fourth quarter, the company recorded revenue of RMB126.3 million with central laboratory business at RMB44.0 million, non-GAAP gross profit of RMB101.4 million, and a non-GAAP gross margin of 80.3%.
- The ELSA-seq patent grant and December 2025 CanCatch� Custom MRD study reinforce Burning Rock Biotech Limited’s R&D with 'ctDNA-based MRD detected by CanCatch� Custom associates with recurrence in CRC'.
- Commercial traction continues as in-hospital business revenue grew to RMB51.0 million for the quarter, driven by contracted partner hospitals and pipeline partner hospitals.
Insights by Ground AI
58 Articles
58 Articles
The Billings Gazette+8 Reposted by 8 other sources
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025.
·Billings, United States
Read Full Article
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central…
Coverage Details
Total News Sources58
Leaning Left12Leaning Right3Center17Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 38%
C 53%
Factuality
To view factuality data please Upgrade to Premium
